Mutant NPM 1 Maintains th e Leukemic State through HOX Expression Graphical Abstract Highlights
暂无分享,去创建一个
Charles Y. Lin | Dennis L. Buckley | B. Falini | M. Goodell | L. Brunetti | B. Nabet | Anna G. Guzman | P. Sportoletti | F. Milano | D. Sorcini | M. Martelli | Yung-Hsin Huang | Michael Gundry | R. Ramabadran | Ilaria Gionfriddo | Federica Mezzasoma | S. Kornblau | A. Guzman | Michael C. Gundry | Behnam Nabet
[1] M. Minden,et al. Abstract 2991: Cytoplasmic mislocalization of CTCF by NPM1c in acute myeloid leukemia resulting in inhibited CTCF regulatory functions generating aberrant genetic and epigenetic profiles , 2018, Molecular and Cellular Biology / Genetics.
[2] M. Goodell,et al. Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9 , 2018, Journal of visualized experiments : JoVE.
[3] James E. Bradner,et al. The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.
[4] C. Hofmeister,et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. , 2018, Blood.
[5] R. Andrews,et al. Molecular synergy underlies the co-occurrence patterns and phenotype of NPM 1-mutant 1 acute myeloid leukemia . 2 3 , 2017 .
[6] Nathanael S Gray,et al. MELK is not necessary for the proliferation of basal-like breast cancer cells , 2017, eLife.
[7] R. Garzon,et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. , 2017, Blood.
[8] Eric S. Lander,et al. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras , 2017, Cell.
[9] M. Minden,et al. Biological and clinical consequences of NPM1 mutations in AML , 2017, Leukemia.
[10] B. Falini,et al. The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed , 2016 .
[11] R. Carlson,et al. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Margaret A Goodell,et al. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. , 2016, Cell reports.
[13] R. Carlson,et al. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Richard L. Halpert,et al. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer , 2016, Clinical Cancer Research.
[15] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[16] Roland Eils,et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins , 2016, Nature.
[17] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[18] D. Grimwade,et al. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.
[19] K. Kawakami,et al. Chromatin-prebound Crm1 recruits Nup98-HoxA9 fusion to induce aberrant expression of Hox cluster genes , 2016, eLife.
[20] S. Armstrong,et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. , 2016, Cancer discovery.
[21] B. Falini,et al. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics , 2015, British journal of haematology.
[22] Charles E. Vejnar,et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR/Cas9 targeting in vivo , 2015, Nature Methods.
[23] Nathan C. Sheffield,et al. ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors , 2015, Nature Methods.
[24] B. Falini,et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. , 2015, Blood.
[25] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[26] R. Fulton,et al. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells , 2015, Leukemia.
[27] E. Baloglu,et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer , 2014, Journal of Hematology & Oncology.
[28] Andrew L. Kung,et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. , 2014, Molecular cell.
[29] Fidel Ramírez,et al. deepTools: a flexible platform for exploring deep-sequencing data , 2014, Nucleic Acids Res..
[30] Howard Y. Chang,et al. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.
[31] James J Collins,et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. , 2013, Cell stem cell.
[32] N. Bolli,et al. The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. , 2013, Blood.
[33] G. Pruneri,et al. NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model , 2013, Leukemia.
[34] O. Dovey,et al. A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice , 2013, Leukemia.
[35] Yong Zhang,et al. Identifying ChIP-seq enrichment using MACS , 2012, Nature Protocols.
[36] Guido Marcucci,et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. , 2012, Blood.
[37] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[38] P. Aplan,et al. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. , 2011, Blood.
[39] Hongwei Ma,et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. , 2011, Blood.
[40] William Stafford Noble,et al. FIMO: scanning for occurrences of a given motif , 2011, Bioinform..
[41] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[42] Stephen A. Ramsey,et al. Genome-wide histone acetylation data improve prediction of mammalian transcription factor binding sites , 2010, Bioinform..
[43] Toshiki Watanabe,et al. Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line. , 2010, Leukemia research.
[44] S. Pileri,et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications , 2009, Leukemia.
[45] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[46] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[47] N. Bolli,et al. A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia , 2008, Leukemia.
[48] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[49] S. Fröhling,et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. , 2007, Cancer cell.
[50] R. Humphries,et al. Hox genes in hematopoiesis and leukemogenesis , 2007, Oncogene.
[51] Brunangelo Falini,et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. , 2007, Cancer research.
[52] Brunangelo Falini,et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.
[53] Pier Paolo Pandolfi,et al. Nucleophosmin and cancer , 2006, Nature Reviews Cancer.
[54] W. Hiddemann,et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.
[55] G. Daley,et al. Embryonic stem cell-derived hematopoietic stem cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[56] N. Bolli,et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin , 2005, Leukemia.
[57] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[58] P. Pandolfi,et al. Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.
[59] Natalia Meani,et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.
[60] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[61] Søren Brunak,et al. Analysis and prediction of leucine-rich nuclear export signals. , 2004, Protein engineering, design & selection : PEDS.
[62] J. Downing,et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. , 2002, Blood.
[63] G. Daley,et al. HoxB4 Confers Definitive Lymphoid-Myeloid Engraftment Potential on Embryonic Stem Cell and Yolk Sac Hematopoietic Progenitors , 2002, Cell.
[64] Minoru Yoshida,et al. CRM1 Is an Export Receptor for Leucine-Rich Nuclear Export Signals , 1997, Cell.
[65] U. Thorsteinsdóttir,et al. Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation. , 1997, Immunity.
[66] G. Sauvageau,et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.